URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Wendy Dixon Biography and Net Worth

Director of Incyte

Dr. Wendy L. Dixon, Ph.D., is an Independent Director of Incyte Corporation. Dr. Dixon served as Chief Marketing Officer and President, Global Marketing for Bristol Myers Squibb Company from December 2001 until May 2009 and served on the Chief Executive Officer's Executive Committee. From 1996 to 2001 she was Senior Vice President, Marketing—USHH at Merck & Co., Inc., and prior to that she held executive management positions at West Pharmaceuticals, Osteotech, Inc. and Centocor, Inc. and various positions at SmithKline & French Pharmaceuticals in marketing, regulatory affairs, project management and as a biochemist.

What is Wendy L. Dixon's net worth?: The estimated net worth of Wendy L. Dixon is at least $4.56 million as of June 10th, 2021. Dr. Dixon owns 66,300 shares of Incyte stock worth more than $4,564,092 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Dixon may own. Learn More about Wendy L. Dixon's net worth.
How do I contact Wendy L. Dixon?: The corporate mailing address for Dr. Dixon and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Wendy L. Dixon's contact information.
Has Wendy L. Dixon been buying or selling shares of Incyte?: Wendy L. Dixon has not been actively trading shares of Incyte during the past quarter. Most recently, Wendy L. Dixon sold 20,000 shares of the business's stock in a transaction on Thursday, December 23rd. The shares were sold at an average price of $22.05, for a transaction totalling $441,000.00. Learn More on Wendy L. Dixon's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (CEO & Chairman), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 65,984 shares worth more than $4,322,270.69. The most recent insider tranaction occured on December, 16th when insider Thomas Tray sold 650 shares worth more than $45,051.50. Insiders at Incyte own 17.6% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 12/16/2024.

Wendy L. Dixon Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/23/2021	Sell	20,000	$22.05	$441,000.00
11/8/2019	Sell	41,218	$83.87	$3,456,953.66	22,916
11/6/2019	Sell	10,576	$84.16	$890,076.16	22,916

Wendy L. Dixon Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $68.84

$66.89

$69.11

50 Day Range

MA: $72.42

$65.07

$83.38

2 Week Range

Now: $68.84

$50.35

$83.95

Volume

6,766,739 shs

Average Volume

2,352,675 shs

Market Capitalization

$13.26 billion

P/E Ratio

491.75

Dividend Yield

N/A

Beta

0.69

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now